pathologies both in humans and animal models 4-6 , and have been linked to cognitive dysfunction 1 in patients with small vessel disease 7 . 2
In mice, a high salt diet (HSD) induces cognitive dysfunction by targeting the cerebral 3 microvasculature through a gut-initiated adaptive immune response mediated by Th17 4 lymphocytes 8 . The resulting increase in circulating IL17 leads to inhibition of endothelial nitric 5 oxide (NO) synthase (eNOS) and reduced NO production in cerebral microvessels, which, in turn, 6 impairs the endothelial regulation of microvascular flow and lowers cerebral blood flow (CBF) by 7 ≈25% 8 . Remarkably, the increases in CBF evoked by neural activity and blood-brain permeability 8 are not altered 8 . However, it remains unclear how hypoperfusion, in HSD as in other vascular risk 9 factors, leads to impaired cognition. The prevailing view is that reduced CBF compromises the 10 delivery of oxygen and glucose to energy-demanding brain regions involved in cognitive 11 function 15, 19 . But the relatively-small reductions in CBF associated with HSD 8 and vascular 12 cognitive impairment 20 do not reach the threshold needed to induce sustained cognitive 13 dysfunction (≥50% CBF reduction) 21, 22 . Thus, vascular factors beyond cerebral perfusion could 14 also be involved. 15
To address this question, we investigated whether tau contributes to the cognitive 16 impairment induced by HSD and, if so, whether the effect depends on the associated cerebral 17 hypoperfusion. First, we established if HSD induces tau phosphorylation. Male C56Bl/6 mice were 18 placed on a normal diet (ND) or HSD (4 or 8% NaCl), corresponding to a 8-16 fold increase over 19 the salt content in the regular mouse chow and approaching the highest levels of human salt 20 consumption 23 . Phosphorylation of selected tau epitopes linked to tau aggregation and neuronal 21 dysfunction 17 were assessed 4, 8, 12, and 24 weeks later by Western blotting. HSD (8%) 22 increased p-tau (AT8, RZ3 epitopes) in neocortex and hippocampus without upregulation of total 23 tau (Tau 46) ( Fig. 1A) . In the hippocampus, an increase in PHF13 was also observed (Extended 24 Data Fig. 1A ). HSD did not increase tau acetylation, a post translational modification implicated 25 in the harmful neuronal effects of tau 24 (Extended data Fig. 1A ). AT8 and RZ3 were also increased 26 in neocortex of female mice fed a HSD (Extended data Fig. 1B ). AT8 and MC1 immunoreactivity was detected in neuronal cell bodies of the pyriform cortex and other cortical regions, but 1 neurofibrillary tangles were not observed ( Fig Fig. 1E ). Increased AT8 was also observed in neocortex with a 4% HSD 4 (Extended Data Fig. 1F ), indicating that also lower amounts of dietary salt are sufficient to induce 5 tau phosphorylation. 6
In neocortex, the increase in AT8 was observed at 4 weeks of HSD and was greatest at 7 24 weeks, whereas in hippocampus p-tau peaked at 12 weeks and then declined ( Fig. 1D and 8
Extended Data Fig. 1G ). An increase in RZ3 was observed at 8 and 12 weeks in neocortex and 9 at 12 weeks in the hippocampus (Extended Data Fig. 1G ). Starting at 12 weeks of HSD, mice 10 exhibited difficulties in recognizing novel objects and developed a deficit in spatial memory at the 11 Barnes maze, suggesting impaired cognition ( Fig.1E ; Extended Data Fig. 2A ). Therefore, tau 12 phosphorylation occurs in parallel with the endothelial NO deficit previously described 8 and is 13 followed by cognitive deficits. To determine if p-tau is upregulated also in other conditions 14 associated with endothelial dysfunction, we investigated models of hypertension in which deficits 15 in endothelial NO and cognitive function are well described 25 . We found an increase in p-tau in 16 hypertension produced by chronic administration of the pressor peptide angiotensin-II or in 17 BPH/2J mice with life-long elevations in blood pressure (Extended Data Fig. 2B -C). 18
Tau solubility is a critical determinant of its harmful neuronal effects, and insoluble tau has 19 been implicated in the neuronal dysfunction driving cognitive impairment 17 . To determine whether 20 HSD alters tau solubility, tau levels were examined in neocortical and hippocampal lysates by 21
Western blotting after sequential biochemical extraction in RAB (salt buffer), RIPA (detergent 22 buffer) or 70% formic acid (FA), containing, respectively, soluble, less soluble and highly insoluble 23 tau. After 12 weeks of HSD the tau in RIPA and FA fractions increased in neocortex and 24 hippocampus, consistent with an increase in more insoluble tau ( Fig. 1F-G ). Since hypothermia 25 in the setting of hibernation increases p-tau levels without causing cognitive impairment 26 , we 26 performed a similar analysis in the brain of mice subjected to hypothermia. We found that hypothermia increases p-tau, but, at variance with HSD, does not produce a shift towards more 1 insoluble species (Extended Data Fig. 2D -E). These observations indicate that HSD leads to tau 2 phosphorylation and a shift from soluble to insoluble tau. 3
The NO precursor L-arginine counteracts the deficit in endothelial NO induced by HSD 8 4 and other conditions associated with endothelial dysfunction 27,28 . Therefore, we asked if L-5 arginine would also rescue the p-tau accumulation induced by HSD and, if so, whether the effect 6 is associated with improved cognition. To this end, mice were given L-arginine in the drinking 7 water (10gr/L) during the last 4 weeks of the HSD or ND 12 week-treatment. We have previously 8 demonstrated that L-arginine normalizes resting and stimulated cerebral endothelial NO synthesis 9 without affecting arterial pressure 8 . L-arginine suppressed p-tau accumulation both in neocortex 10 (AT8 and RZ3) and hippocampus (AT8) and prevented the cognitive dysfunction induced by HSD 11 ( Fig Cdk5 is a major kinase responsible for tau hyperphosphorylation 29 . Cdk5 activity is tightly 13 regulated by its protein binding partners, including p35 30 . In conditions associated with neuronal 14 stress, cleavage of p35 into p25 by calpain leads to dysregulated activation of Cdk5 and 15 hyperphosphorylation of its targets, including tau 31,32 . Since reduced endothelial NO may lead to 16 tau phosphorylation by activating Cdk5 via p25 33 , we examined if HSD influences calpain and 17 Cdk5 activity. Calpain 2 is more abundant than calpain 1 in neocortex ( Fig. 3A) , is located mainly 18 in neurons (Extended Data Fig. 3B ) 34 and colocalizes with Cdk5 (Extended Data Fig. 3C ). HSD 19 did not alter calpain expression ( Fig. 3A ), but resulted in activation of the enzyme, leading to an 20 increase in the p25/p35 ratio, in Cdk5 bound to p25/p35 and in Cdk5 catalytic activity ( Fig. 3A-C) . 21
Attesting to the involvement of endothelial NO, L-arginine administration prevented the calpain 22 activation induced by HSD and the resulting increase in the Cdk5/p25/p35 complex and enzyme 23 activation ( Fig. 3D-E ). L-arginine did not alter calpain levels (Extended Data Fig. 3D ). GSK3β has 24 also been implicated in tau phosphorylation, but HSD did not increase the activity of this enzyme 25 in neocortex (Extended Data Fig. 3E ). Similarly, HSD did not alter the expression of the prolyl 26 cis/trans isomerase Pin-1, a regulator of tau dephosphorylation 35 (Extended Data Fig. 3F ).
Next, we examined the potential mechanisms by which endothelial NO deficiency may 1 influence calpain activity. Calpain, once activated by Ca 2+ , is regulated mainly by its endogenous 2 inhibitor calpastatin and by nitrosylation by NO 36 , which suppress calpain activity 37 . Since HSD 3 did not reduce calpastatin expression (Extended Data Fig. 3G ), we used the biotin switch assay 4 to investigate the effect of HSD on calpain nitrosylation. Consistent with the observed calpain 5 activation, we found that HSD reduces calpain nitrosylation ( Fig. 3F ). 6
The findings thus far suggest that HSD leads to neuronal p-tau accumulation through a 7 deficit in endothelial NO resulting in denitrosylation and activation of calpain, which, in turn 8 increases p25 levels resulting in activation of Cdk5. However, HSD also lowers resting CBF and 9 impairs the ability of endothelial cells to regulate CBF, which could contribute to impair cognition 10 by reducing the delivery of oxygen and glucose to brain regions involved in cognitive function 19, 38 . 11 Therefore, we examined the relative contribution of p-tau and neurovascular dysfunction to the 12 cognitive deficits induced by HSD. We reasoned that if tau is critical for the cognitive dysfunction, 13
then tau-null mice should be protected from the deleterious cognitive effects of HSD despite 14 sustained cerebral hemodynamic dysfunction. Tau-null mice were placed on ND or HSD and 15 cerebral endothelial vasomotor function and cognition were assessed 12 weeks later. As 16 anticipated 39 , the performance of tau-null mice to the novel object recognition test and Barnes 17 maze was not different from that of WT controls fed a ND ( Fig. 4A -C). Tau-null mice on HSD did 18 not exhibit cognitive impairment, but still exhibited marked endothelial dysfunction, as reflected 19 by the suppression of the CBF increase induced by bathing the neocortex with acetylcholine ( Fig.  20 4D), a prototypical endothelial response mediated by eNOS-derived NO 38 . Therefore, it would 21 seem that CBF dysregulation is not required for the cognitive dysfunction of HSD. To provide 22 further evidence in support of this conclusion we treated WT mice with anti-tau antibodies (HJ8.8) 23 or control IgG (50 mg/kg/week; i.p.) for the last 4 weeks of the 12-week ND or HSD regimen 40 . 24
Anti-tau antibodies were previously shown to ameliorate cognitive function in a tauopathy mouse 25 model 40 . In HJ8.8-treated mice, HSD induced a reduction in resting CBF and an attenuation of 26 the endothelial CBF response to acetylcholine comparable to that observed in HSD-fed mice treated with control IgG (Fig. 4E-F ). Despite persistent hypoperfusion and endothelial dysfunction, 1 anti-tau antibodies ameliorated the cognitive deficit induced by HSD (Fig. 4G ). The effect was 2 associated with a reduction in p-tau in neocortex (AT8) and hippocampus (AT8 and RZ3) ( Fig.  3 4H). As before 8 , HSD did not affect the increases in CBF induced by neural activity (Extended 4 Data Fig. 4A ) 5
These observations, collectively, are consistent with the hypothesis that the reduction in 6 endothelial NO induced by HSD leads to calpain denitrosylation resulting in activation of the 7 enzyme. The ensuing increase in p25 activates Cdk5 leading to tau phosphorylation in neurons, 8 which, in turn, is responsible for the cognitive impairment (Extended Data Fig. 4C ). In addition, 9
the data indicate that the neurovascular dysfunction associated with HSD, also caused by the NO 10 deficit, is not critical for the cognitive dysfunction. This conclusion is supported by the observations 11 that the cognitive deficits induced by HSD do not occur in tau-null mice and are ameliorated by 12 anti-tau antibodies, despite altered endothelium-dependent vasodilatation and reduced CBF. 13
The findings provide novel insights into the mechanisms by which cerebrovascular 14 dysfunction alters cognition. Although to be confirmed in other cerebrovascular risk factors, the 15 CBF reduction and suppression of endothelium-dependent vasoreactivity associated with HSD 16 do not drive cognitive impairment. Whereas the suppression in endothelial NO induced by HSD 17 is required for the cognitive impairment, the hemodynamic consequences of such NO deficit do 18 not play a role. Rather, the cognitive dysfunction is dependent on the tau phosphorylation 19 promoted by the deficit in endothelial NO. Thus, the cerebral hypoperfusion resulting from NO 20 deficiency seems to be inconsequential to the cognitive deficit. Other aspects of endothelial 21 function are at play, namely endothelial NO maintaining calpain homeostasis and preventing Cdk5 22 dysregulation and tau hyperphosphorylation. 23
Our data also provide a previously-unrecognized link between dietary habits, vascular 24 dysfunction and tau pathology, independently of cerebral hypoperfusion. Such relationship may 25 play a role in the frequent overlap between vascular and neurogenerative pathologies underlying 26 late-life dementia 41 . Whereas avoiding excessive salt consumption may help prevent tau pathology, therapeutic efforts to counteract cerebrovascular dysfunction need to go beyond 1 rescuing cerebral perfusion, and target vascular mediators governing neurovascular interactions 2 critical for cognitive health. Male or female mice (8 weeks old) received normal chow (0.5% NaCl) and tap water ad libitum 19 (normal diet) or sodium-rich chow (4-8% NaCl) and tap water containing 1% NaCl ad libitum 20 (HSD) for 4 to 24 weeks according to the experiment 8 . 21
22
In vivo treatments 23
The nitric oxide precursor, L-arginine (10gr/L; Sigma) was administered in the drinking water 24 starting at 8 weeks of HSD and continuing until 12 weeks. ND and HSD mice were treated (i.p., 25 weekly) with 50mg/kg of anti-Tau (HJ8.8) or mouse IgG1 isotype control (Clone MOPC-21; bioXcell) antibodies for the last 4 weeks of the HSD treatment period (12 weeks) prior to 1 behavioral and cerebrovascular studies. Mice were anesthetized with isoflurane (induction, 5%; maintenance, 2%). The trachea was 5 intubated and mice were artificially ventilated with a mixture of N2 and O2. One of the femoral 6 arteries was cannulated for recording mean arterial pressure (MAP) and collecting blood samples 7 for blood gas analysis 43 . Rectal temperature was maintained at 37°C. End tidal CO2, monitored 8 by a CO2 analyzer (Capstar-100, CWE Inc.), was maintained at 2.6-2.7% to provide a pCO2 of 9 30-40 mmHg and a pH of 7.3-7.437. After surgery, isoflurane was discontinued and anesthesia 10 was maintained with urethane (750 mg/kg, i.p.) and chloralose (50 mg/kg, i.p.). Throughout the 11 experiment the level of anesthesia was monitored by testing motor responses to tail pinch. 
Protocol for CBF experiments 21
After MAP and blood gases stabilized, CBF responses were recorded 8 . The whisker-barrel cortex 22 was activated for 60 seconds by stroking the contralateral vibrissae, and the evoked changes in 23 CBF were recorded. The endothelium-dependent vasodilator acetylcholine (ACh; 100µM; Sigma), 24 was superfused on the exposed neocortex for 5 minutes and the associated CBF changes were 25 recorded by laser-Doppler flowmetry. 26 Measurement of resting CBF by ASL-MRI 1 CBF was assessed quantitatively using arterial spin labeling magnetic resonance imaging (ASL-2 MRI) as previously described 8 . The ASL images were analyzed by ImageJ and the average CBF 3 value is reported as mL per 100g of tissue per minute. 4 5
Osmotic minipumps implantation 6
Osmotic minipumps containing vehicle (saline) or ANG II (600 ng·kg−1·min−1) were implanted 7 subcutaneously under isoflurane anesthesia. Systolic blood pressure was monitored in awake 8 mice using tail-cuff plethysmography 25 . Forty-two days later, mice were anesthetized and their 9 brains were collected for assessment of tau phosphorylation. 10 11 Hypothermia 12 C57BL/6 mice (12 weeks old) were anesthetized by injection of ketamine/xylazine (100/10 13 mg/kg). Rectal temperature was continuously monitored and kept at 37˚C (normothermia) or 30˚C 14 (hypothermia) using a thermostatically-controlled heating pad. Mice were sacrificed 30 minutes 15 after anesthesia and their brains were collected and frozen on dry ice. Tissues were kept at −80°C 16 until processing for immunoblot analysis. 17 18
Immunoblot analysis 19
Cortex (≈80-90mg) and hippocampus (≈15mg) isolated from ND and HSD mice were sonicated 20 in 800 and 600μl of RIPA buffer (50mM Tris-HCl pH 8.0, 150mM NaCl, 0.5% Deoxycholic Acid, 21 0.1% SDS, 1mM EDTA pH 8.0, 1% IGEPAL CA-630, 1mM Na3VO4, 20mM NaF and one 22 tablet/10mL of cOmplete™, EDTA-free Protease Inhibitor Cocktail, Millipore Sigma) and equal 23 volumes were mixed with SDS sample buffer, boiled, and analyzed on 10% or 10-20% Novex™ 24
WedgeWell™ gels (Thermo Fisher Scientific). Proteins were transferred to PVDF membranes 25 (Millipore), blocked at room temperature (RT) for 1 hour with 5% milk in TBS, and incubated, 26 overnight at 4˚C, with primary antibodies (see Extended Data Table 1) in 5% BSA in TBS/0.1% Tween-20 (TBST). Membranes were washed in TBST, incubated with goat anti-mouse or rabbit 1 secondary antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology) for 1 2 hour at RT and protein bands were visualized with Clarity Western ECL Substrate (Bio Rad) on a 3 Bio Rad ChemiDoc MP Imaging System. Quantification was performed using Image Lab 6.0 (Bio 4 Rad). 5 6
Heat-stable fractions 7
After homogenization in cold RIPA buffer and centrifugation, 150µl of the supernatant containing 8 the proteins was boiled at 100˚C for 10 minutes. Samples were cooled on ice for 20 minutes and 9 then centrifuged at 20,000 g at 4˚C for 15 minutes. The supernatant corresponding to the heat 10 stable (HS) fraction was then harvested. This method is used to isolate proteins resistant to heat 11 including tau and other microtubule-associated proteins (MAPs). Thus, endogenous 12 immunoglobulins are precipitated during the boiling process and eliminated from the supernatant. 13
The proteins were then mixed with equal volumes of SDS sample buffer, boiled, and analyzed on 14 Reactions were stopped by addition of SDS sample buffer and boiling for 5 minutes at 100 ˚C. 24 25 Brain tissue protein extraction Extraction was performed as described previously 40 . The cortex (≈80-90mg) and the 1 hippocampus (≈15mg) of each brain were homogenized by sonication in 800 and 300μl of RAB 2 buffer [100mM MES, 1mM EDTA, 0.5mM MgSO4, 750mM NaCl, 20mM NaF, 1mM Na3VO4, 3 supplemented by EDTA-free Protease Inhibitor Cocktail, Millipore Sigma], respectively. In brief, 4 the samples were centrifuged at 50,000g for 20 minutes at 4°C using an Optima MAX-TLA 120.2 5 Ultracentrifuge (Beckman). The supernatants were collected as RAB soluble fractions and pellets 6 were resuspended in identical volumes of RIPA buffer [150mM NaCl, 50mM Tris, 0.5% 7 deoxycholic acid, 1% Triton X-100, 0.5% SDS, 25mM EDTA, pH 8.0, 20mM NaF, 1mM Na3VO4 8 supplemented by EDTA-free Protease Inhibitor Cocktail, Millipore Sigma], and centrifuged at 9 50,000 g for 20 minutes at 4°C. The supernatants were collected as RIPA soluble fractions. The 10 pellets were sonicated in 70% formic acid (300μl for the cortex and 125μl for the hippocampus), 11 and centrifuged at 50,000g for 20 minutes at 4°C. The supernatants were collected as 70% formic 12 acid fractions. All fractions were stored in -80°C until analyzed. For western blotting, an aliquot of 13 After 12 weeks of ND/HSD, mice were anesthetized with intraperitoneal pentobarbital (200 19 mg/kg), and then perfused transcardiacally with cold PBS, followed by cold 4% paraformaldehyde 20 (PFA) in PBS. The brains were removed and immersed first in 4% PFA overnight and then in 70% 21 ethanol for 3 days. Brains were then embedded in paraffin and cut into 6μm sections using a 22 microtome. After rehydration and antigen retrieval in preheated citrate buffer (10μM) for 30 23 minutes, brain sections were immersed in 3% H 2O2 and then blocked with 100% Sniper (Biocare 24 Medical) for 1 hour. After blocking, sections were incubated for 2.5 days at 4°C with the AT8, 25 MC1, Calpain 2 or Cdk5 antibody (1:250, 1:100, 1:100 and 1:100 in 1:50 Sniper in PBS, 26 respectively) and thereafter processed for 1 hour with the biotinylated secondary antibody in 1% normal donkey serum PBS (anti-mouse IgG1, Jackson ImmunoResearch) or Cy3 anti-rabbit and 1 FITC anti-mouse (Jackson ImmunoResearch) for immunofluorescence studies. Reactions were 2 visualized with the ABC-complex (Vectorlabs) and 3,3-diaminobenzidine. A Nikon light 3 microscope or a confocal microscope (Leica TCS SP5) was used to visualize the signal 4 associated with each antibody. 5 6 Thioflavin S Staining 7
After mounting on slides and post-fixation with 4% PFA in PBS for 10 minutes, coronal brain 8 sections (40µm) were washed and labeled with 0.05% (wt/vol) thioflavine-S in 50% (vol/vol) 9 ethanol for 10 minutes as previously described 45 . An epifluorescence microscope (IX83 Inverted 10 Microscope, Olympus) was used to visualize the FITC signal associated with thioflavine-S. Signaling) or anti-rabbit monoclonal IgG1 isotype control antibody (Santa Cruz Biotechnology).
Samples were incubated overnight with the primary antibodies and then with protein-A sepharose 1 (p35p25) (GE Healthcare Life Sciences) or protein-G Dynabeads (GSK3β) (Thermo Fisher 2 Scientific) for 2 hours at 4º C. Precipitates were used for Cdk5 or GSK3β activity measurements. 3
Immunoprecipitation was confirmed by loading the samples on 10% Tris-glycine SDS 4 polyacrylamide gels and western blot as described above. 5 6
Detection of S-nitrosylation of calpain 2 with the biotin-switch technique 7
Detection of S-nitrosylated calpain 2 was performed using the biotin-switch technique, as 8 previously described 48 . Briefly, samples were sonicated in 800μl of RIPA buffer containing 0.1mM 9 of neocuproine and, after centrifugation, protein concentrations were measured. Cysteine thiol 10 groups in 1mg of proteins were blocked with 10% S-methylmethane thiosulfonate (MMTS) 11 (Sigma). After protein-precipitation with 100% acetone, sodium ascorbate was added to the 12 sample to convert each S-nitrothiols (SNO) to a free thiol via a transnitrosation reaction to 13 generate O-nitrosoascorbate. Next, each nascent free thiol (previously an SNO site) was 14 biotinylated with biotin-HPDP (Pierce). Biotinylated proteins were then pull-down by using avidin 15 beads and analyzed on 10% Novex™ WedgeWell™ gels (Thermo Fisher Scientific). Before avidin 16 pulldown, a small fraction of each sample was collected to determine protein "input." The degree 17 of pulldown correlates with protein S-nitrosylation of calpain 2 which was detected with an 18 antibody against the protein (see Extended Data Suppl. Table 1 ). Nitrosylation of calpain 2 is 19 expressed as the ratio between the pull-down signal and the input corrected for the β-actin levels. 20 21
Cdk5 and GSK3β activity 22
Cdk5 activity in brain lysates was determined after pulldown with p25/p35 antibody (Cell 23 Signaling) from 500µg total protein using a synthetic histone H1 peptide substrate 24 (PKTPKKAKKL, Enzo Life Sciences). GSK3β activity was determined after pulldown with GSK3β 25 antibody (Cell Signaling) from 100µg total protein using phospho-glycogen synthase peptide-2a 26 as substrate (Tocris). Phosphorylation reactions were initiated by mixing bead-coupled Cdk5 with 40µl reaction buffer containing the following: 50mM HEPES.KOH (pH 7.4), 5mM MgCl2, 0.05% 1 BSA, 50µM substrate, 50µM cold ATP, 1mM dithiothreitol, 1x complete protease inhibitors without 2 EDTA (Roche Applied Biosciences) and 5 Ci/mmole γ32 P-ATP. Companion reactions for every 3 sample were executed in the presence of the Cdk5 inhibitor ((R)-CR8, Tocris) (10µM) or the 4 GSK3β inhibitor (CHIR 99021, Tocris) (10µM) to correct for non-specific activity. Reactions were 5 incubated at 30°C for 30 minutes, after which they were terminated by spotting on P81 6 phosphocellulose cation exchange chromatography paper. Filters were washed 4 times for 2 7 minutes in 0.5% phosphoric acid, and the remaining radioactivity was quantified in a scintillation 8 counter by the Cherenkov method. 9 10
Novel Object Recognition Test 11
The novel object recognition test (NOR) task was conducted under dim light in a plastic box. 12
Stimuli consisted of plastic objects that varied in color and shape but had similar size 49,50 . A video 13 camera mounted on the wall directly above the box was used to record the testing session for off-14 line analysis. Mice were acclimated to the testing room and chamber for one day prior to testing. 15
Twenty-four hours after habituation, mice were placed in the same box in the presence of two 16 identical sample objects and were allowed to explore for 5 minutes. After an intersession interval 17 of 1 hour, mice were placed in the same box but one of the two objects was replaced by a novel 18 object. Mice were allowed to explore for 5 minutes. Exploratory behavior was later assessed 19 manually by an experimenter blinded to the treatment group. Exploration of an object was defined 20 as the mouse sniffing the object or touching the object while looking at it. Placing the forepaws on 21 the objects was considered as exploratory behavior but climbing on the objects was not. The Barnes maze consisted of a circular open surface (90cm in diameter) elevated to 90cm by 1 four wooden legs 51 . There were 20 circular holes (5cm in diameter) equally spaced around the 2 perimeter, and positioned 2.5cm from the edge of the maze. No wall and no intra-maze visual 3 cues were placed around the edge. A wooden plastic escape box (11×6×5cm) was positioned 4 beneath one of the holes. Two neon lamps and a buzzer were used as aversive stimuli. The Any-5
Maze tracking system (Stoelting) was used to record the movement of mice on the maze. Extra-6 maze visual cues consisted of objects within the room (table, computer, sink, door, etc.) and the 7 experimenter. Mice were tested in groups of seven to ten, and between trials they were placed 8 into cages, which were placed in a dark room adjacent to the test room for the inter-trial interval 9 (20-30 minutes). No habituation trial was performed. The acquisition phase consisted of 3 10 consecutive training days with three trials per day with the escape hole located at the same 11 location across trials and days. On each trial a mouse was placed into a start tube located in the 12 center of the maze, the start tube was raised, and the buzzer was turned on until the mouse 13 entered the escape hole. After each trial, mice remained in the escape box for 60 seconds before 14 being returned to their cage. Between trials the maze floor was cleaned with 10% ethanol in water 15 to minimize olfactory cues. For each trial mice were given 3 minutes to locate the escape hole, 16 after which they were guided to the escape hole or placed directly into the escape box if they 17 failed to enter the escape hole. Four parameters of learning performance were recorded: (1) the 18 latency to locate (primary latency) and (2) enter the escape hole (total latency), (3) the number of 19 errors made and (4) the distance traveled before locating the escape hole 51 . When a mouse 20 dipped its head into a hole that did not provide escape was considered an error. On days 4 and 21 5, the location of the escape hole was moved 180° from its previous location (reverse learning) 22 and two trials per day were performed. 
